| 0.5401 0.008 (1.48%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.7 | 1-year : | 0.81 |
| Resists | First : | 0.6 | Second : | 0.69 |
| Pivot price | 0.57  |
|||
| Supports | First : | 0.45 | Second : | 0.38 |
| MAs | MA(5) : | 0.56 |
MA(20) : | 0.57 |
| MA(100) : | 0.74 |
MA(250) : | 1.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.1 |
D(3) : | 49.5 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 3.88 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GOVX ] has closed above bottom band by 15.9%. Bollinger Bands are 69% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.52 - 0.52 | 0.52 - 0.52 |
| Close: | 0.53 - 0.53 | 0.53 - 0.54 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Fri, 17 Oct 2025
GeoVax Labs (GOVX) Files to Sell 11.9 Million Shares - GuruFocus
Tue, 30 Sep 2025
GeoVax Labs Raises $2.5 Million in Direct Offering - TipRanks
Tue, 30 Sep 2025
GeoVax Labs Announces $2.5 Million Registered Direct Offering - Yahoo Finance
Fri, 26 Sep 2025
D. Boral Capital Maintains GeoVax Labs (GOVX) Buy Recommendation - Nasdaq
Wed, 20 Aug 2025
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Tue, 19 Aug 2025
GeoVax Labs Stock (GOVX) Opinions on Vaccine Market Developments - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.991e+007 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 4,070 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.494e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -635.9 % |
| Return on Assets (ttm) | -331.2 % |
| Return on Equity (ttm) | -9 % |
| Qtrly Rev. Growth | 6.14e+006 % |
| Gross Profit (p.s.) | 55.27 |
| Sales Per Share | 207.9 |
| EBITDA (p.s.) | -5.70783e+006 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 9.98 |
| Dividend | 0 |
| Forward Dividend | 3.7e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|